Tekla Capital Management LLC Has $117,947,000 Holdings in Amgen, Inc. (AMGN)
Tekla Capital Management LLC maintained its stake in shares of Amgen, Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 684,824 shares of the medical research company’s stock at the end of the 2nd quarter. Amgen accounts for about 4.4% of Tekla Capital Management LLC’s holdings, making the stock its 4th biggest position. Tekla Capital Management LLC owned about 0.09% of Amgen worth $117,947,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. PGGM Investments increased its position in shares of Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock valued at $115,555,000 after acquiring an additional 15,059 shares during the last quarter. Shelton Capital Management increased its position in shares of Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock valued at $17,883,000 after acquiring an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. increased its position in shares of Amgen by 466.9% during the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock valued at $2,416,000 after acquiring an additional 11,555 shares during the last quarter. Kelman Lazarov Inc. increased its position in shares of Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock valued at $272,000 after acquiring an additional 120 shares during the last quarter. Finally, Osborne Partners Capital Management LLC increased its position in shares of Amgen by 0.5% during the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock valued at $2,932,000 after acquiring an additional 91 shares during the last quarter. 78.38% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the transaction, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The disclosure for this sale can be found here. Insiders sold 7,050 shares of company stock valued at $1,239,673 over the last ninety days. Corporate insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the company earned $3.02 earnings per share. Amgen’s revenue was down .7% compared to the same quarter last year. equities research analysts predict that Amgen, Inc. will post 12.66 EPS for the current year.
Amgen declared that its board has approved a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which was paid on Friday, December 8th. Stockholders of record on Friday, November 17th were issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date of this dividend was Thursday, November 16th. Amgen’s payout ratio is currently 41.63%.
A number of analysts recently commented on AMGN shares. Mizuho reaffirmed a “buy” rating and set a $198.00 price target (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. BMO Capital Markets reaffirmed a “hold” rating and set a $198.00 price target on shares of Amgen in a research report on Friday, October 20th. Jefferies Group reaffirmed a “buy” rating and set a $200.00 price target on shares of Amgen in a research report on Monday, September 25th. Royal Bank Of Canada started coverage on Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target for the company. Finally, Barclays increased their price target on Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $190.22.
ILLEGAL ACTIVITY WARNING: “Tekla Capital Management LLC Has $117,947,000 Holdings in Amgen, Inc. (AMGN)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/10/tekla-capital-management-llc-has-117947000-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.